Acriflavine and proflavine hemisulfate as potential antivirals by targeting MproArticle Published on 2022-12-012022-11-15 Journal: Bioorganic chemistry [Category] COVID19(2023년), SARS, 치료제, [키워드] ACF acriflavine activity addition anti-SARS-CoV-2 Antiviral antiviral target BHK-21 cell Compound Coronaviruses demonstrated effective drugs effort enzymatic assay experiment HCoV-OC43 in vitro Infection inhibited inhibitor inhibitors inhibitory activity M pro M(pro) inhibitor MPro Proflavine Proflavine hemisulfate Remdesivir Replication reported SARS-CoV-2 SARS-CoV-2 epidemic SARS-CoV-2 virus SARS-CoV-2. Transcription Viral RNA [DOI] 10.1016/j.bioorg.2022.106185 PMC 바로가기
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variantsSARS-CoV-2 오미크론 변이체에 감염된 중국 참가자의 VV116에 대한 공개, 전향적 코호트 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration adverse event adverse events anti-SARS-CoV-2 antiviral drug baseline characteristics Chinese Cohort cohort study collected conducted control group COVID-19 Cox regression analysis effective Effectiveness Efficacy enrolled evaluate first positive Follow-up Hospitalized infected with SARS-CoV-2 Infection Intervention median time no significant difference omicron Omicron variant participant Patient preclinical studies predominant Prevalence prospective cohort study receive regression analysis reported resolved robust Safe Serious Adverse Event Serious Adverse Events standard treatment Symptom symptomatic treatment group variant variant of SARS-CoV-2 Viral load Viral load. viral shedding VV116 with COVID-19 [DOI] 10.1080/22221751.2022.2078230 PMC 바로가기 [Article Type] Article
Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodiesArticle Published on 2022-11-082022-11-15 Journal: Scientific Reports [Category] SARS, 치료기술, [키워드] acute respiratory syndrome administration affecting Analysis analysis anti-RBD IgG antibody anti-SARS-CoV-2 AUC automated binding antibody booster clinical settings Cohort collected Control coronavirus correlation COVID-19 cutoff value demonstrated Effectiveness Genscript gold standard Immunity immunoassay in both groups infected patient Mindray NAb neutralization Neutralization assay neutralization test neutralizing antibody population level protective immunity provide pseudovirus R 2 Rapid receiver operating characteristic Research ROC ROC Curve Sample SARS-CoV-2 SARS-CoV-2 infected patient second dose sensitivity shown significantly specificity subjects sVNT sVNT assay symptoms onset tested threshold vaccinated individual Vaccine virus neutralization test was performed [DOI] 10.1038/s41598-022-21317-x PMC 바로가기
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Article Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, [키워드] anti-Nucleocapsid IgG anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antigen booster vaccination cellular cellular immunity Cohort Concentration convalescent COVID-19 detectable domain Endemic humoral IFN-γ IgG immune response Immunity Immunoglobulin Immunosuppressed Immunosuppression immunosuppressive individual liver Liver transplantation membrane nucleocapsid Prevalence protective immunity reactivity Receptor binding domain recipient remained retrieved robust SARS-CoV-2 significantly increased Spike protein stimulated T cell T cell response therapy vaccination [DOI] 10.1371/journal.pone.0276929 PMC 바로가기
Evaluation of five immunoassays and one lateral flow immunochromatography for anti-SARS-CoV-2 antibodies detectionArticle Published on 2022-11-012022-11-15 Journal: Enfermedades infecciosas y microbiologia clinica ( [Category] SARS, 진단, 치료기술, [키워드] addition anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody approach caused CLIA CLIA assays Clinical practice complementary coronavirus SARS-CoV-2 COVID-19 COVID-19 patient criteria diagnostic ELISA English evaluated FIVE greater healthcare worker healthy IgG IgM IgM antibody immunoassay immunochromatographic test immunochromatography Inmunocromatografía involved lateral flow Pandemia pandemic para performed Rapid test ROC ROC curves RT-PCR SARS-CoV-2 SARS-CoV-2 coronavirus sensitivity Serología. serological serology serum sample Sin Spanish specificity Support Vaccine [DOI] 10.1016/j.eimce.2020.12.007 PMC 바로가기
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathiesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 진단, [키워드] Administered administration age Alter analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibodies COVID-19 COVID-19 vaccination COVID-19 vaccine decrease dose enzyme-linked immunosorbent female healthy subjects IgA IgA titer IgG IgG titer IgM immune immunoassay Immunoglobulin impair indicate Interaction intravenous Intravenous immunoglobulin IVIG Microparticle mRNA vaccine observation Patient positive Prevalence reduce remained sera serological response serum serum titer significantly subsequent the antibody response therapeutic vaccination Vaccine vaccine dose vaccine interaction. [DOI] 10.1111/ene.15508 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN studyArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infection [Category] SARS, 진단, 치료기술, [키워드] age analysed anti-S anti-SARS-CoV-2 antibody association Case-control case-control study controls correlated fixed Gender identify Immunity Increasing infected individual Infection Linear regression Live virus logistic regression models Neutralising Antibodies no difference nucleocapsid occurred performed pre-vaccination protective effect pseudovirus reduced risk Reinfection required Result SARS-CoV-2 SARS-CoV-2 serology. serological serology serum sample significantly lower SIREN study tested titre titres vaccination Wuhan [DOI] 10.1016/j.jinf.2022.09.004 PMC 바로가기
Nitazoxanide and COVID-19: A reviewArticle Published on 2022-11-012022-11-15 Journal: Molecular biology reports [Category] SARS, 치료제, [키워드] Activation acute lung injury acute respiratory distress acute respiratory distress syndrome addition Anti-inflammatory anti-parasitic drug anti-SARS-CoV-2 Antiviral antiviral activity antiviral property ARDS autophagic cause cell death clinical trial Coronavirus disease 2019 COVID-19 Cytokine storm Cytokines distress drug effective finding IFN immunological in silico in vitro study Infection inflammatory disorders inflammatory reaction inhibit Innate immunity interferon lung mammalian mitigate Multi-organ damage nitazoxanide oxidative stress pathogenesis of SARS-CoV-2 pro-inflammatory cytokines pro-inflammatory cytokines. Prospective Study Protozoa Rapamycin reduce Respiratory Coronavirus SARS-CoV-2 SARS-CoV-2 infections severe cases syndrome therapy Treatment triggered viral infections Viral pneumonia [DOI] 10.1007/s11033-022-07822-2 PMC 바로가기
Lucidenic acid A inhibits the binding of hACE2 receptor with spike protein to prevent SARS-CoV-2 invasionArticle Published on 2022-11-012022-11-15 Journal: Food and chemical toxicology : an international jo [Category] SARS, 변종, 치료제, [키워드] analyzed anti-SARS-CoV-2 antiviral effects binding caused complexes component components demonstrated exhibit FRET test Ganoderma lucidum triterpenoids hACE2 hACE2 receptor high affinity hydrogen bonds IC50 in vitro Infection inhibit inhibited inhibition assay Invasion Lucidenic acid A (PubChem CID: 14109375) molecular docking molecular dynamics Mutation natural natural products omicron Omicron variant omicron variant. pathway Potential Prevent PubChem receptor receptor proteins SARS-CoV-2 Spike protein stability target variant Virtual screening virus was selected were used [DOI] 10.1016/j.fct.2022.113438 PMC 바로가기